Abstract The prevalence of diabetes mellitus is currently at epidemic proportions and it is estimated that it will increase even further over the next decades. Although genetic predisposition and lifestyle choices are commonly accepted reasons for the occurrence of type 2 diabetes, it has recently been suggested that environmental pollutants are additional risk factors for diabetes development and this review aims to give an overview of the current evidence for this. More specifically, because of the crucial role of pancreatic beta cells in the development and progression of type 2 diabetes, the present work summarises the known effects of several compounds on beta cell function with reference to mechanistic studies that have elucidated how these compounds interfere with the insulin secreting capacity of beta cells. Oestrogenic compounds, organophosphorus compounds, persistent organic pollutants and heavy metals are discussed, and a critical reflection on the relevance of the concentrations used in mechanistic studies relative to the levels found in the human population is given. It is clear that some environmental pollutants affect pancreatic beta cell function, as both epidemiological and experimental research is accumulating. This supports the need to develop a solid and structured platform to fully explore the diabetes-inducing potential of pollutants.
Introduction
Changes in human lifestyle and behaviour (e.g. poor diet, lack of exercise), in addition to genetic predisposition and environmental influences, have resulted in a dramatic increase in the incidence of diabetes mellitus worldwide [1] . This global diabetes epidemic is chiefly due to type 2 diabetes as it makes up more than 90% of all diabetes cases [1] .
Type 2 diabetes results from interactions between genetic susceptibility, environmental factors and lifestyle choices. Our understanding of the causes of diabetes, besides genetics, has remained rudimentary, for the most part being limited to the impact of physical inactivity or unhealthy dietary choices [2] . For obesity, which is closely associated with diabetes, a relationship with environmental endocrinedisrupting compounds (EDCs) has been hypothesised based on epidemiological data and in vivo rodent studies. In this scenario the chemicals that disrupt lipid regulation and adipogenesis are defined as obesogens [3] . Although evidence that environmental pollutants might be an additional risk factor for diabetes development is accumulating, a systematic investigation of the possibility that environmental pollutants could be key players in the aetiology of type 2 diabetes [4] has not yet been performed. However, there are strong experimental indications that some pollutants, such as bisphenol A [5] and certain persistent organic pollutants (POPs) [6] , affect processes that are related to diabetes development.
While reduced insulin sensitivity and beta cell function are the core pathophysiological defects in type 2 diabetes [7] , the relative importance of these abnormalities is still under debate [8] . However, it has recently been acknowledged that beta cell failure is the triggering factor [9] for the progression of pre-diabetic states (impaired glucose tolerance or impaired fasting glucose or both) to full-blown type 2 diabetes. Obviously, investigation of the effects and mechanisms of action of compounds should focus on their roles in both the development and progression of insulin resistance and beta cell dysfunction. To date, with regard to research on environmental causes, insulin resistance has received more attention than beta cell function. However, considering the critical role of pancreatic beta cells in the progression of type 2 diabetes, there is a great need to focus on the impact of chemicals on the function of these cells. This could provide crucial information on normal beta cell function and physiology as well as on compound-specific toxicity.
This review aims to give an overview of the interference of normal beta cell function by environmental pollutants, specifically focusing on proposed mechanisms of disruption of insulin secretion. Furthermore, a critical discussion on the discrepancy between experimental and environmentally relevant exposure concentrations is given, followed by comments on the value of mechanistic studies in human risk assessment.
Insulin secretion
The role of the pancreatic beta cell is to sense an increase in the concentration of nutrients (notably glucose) in the blood and to deliver an appropriate quantity of insulin into the systemic circulation. This ensures that the sugar is efficiently taken up and stored as glycogen or triglycerides by peripheral tissues (liver, muscle and adipose tissue) [10] . Figure 1 summarises the mechanism of glucose-stimulated insulin secretion (GSIS) as currently understood. After the initial, rapid triggering phase mediated by ADP/ATP-sensitive potassium channels (K ATP + channels; Fig. 1 , see label A), additional signals are necessary to produce the sustained secretion elicited by glucose [11] via a K ATP + channel-independent pathway (reviewed in [10] [11] [12] ). Furthermore, to sustain the insulin secretion capacity and the glucose responsiveness of beta cells, glucose also elicits effects at the translational (Fig. 1 , see label D) [13] and transcriptional level ( Fig. 1 , see label C) [14, 15] . Once glucose is taken up via GLUT-2, it is phosphorylated to glucose 6-phosphate by the high K m glucokinase, followed by entry into the glycolytic pathway and mitochondrial oxidation. Mitochondrial ATP production promotes the closure of K ATP + channels, and as a consequence the depolarisation of the plasma membrane. ] i and activation of potentiating proteins triggers exocytosis. After this initial, rapid triggering phase (first phase), the amplification or K ATP + channel-independent pathway (second phase) sustains secretion elicited by glucose. To sustain insulin secretion and adequate nutrient sensing, glucose also directly influences transcription (C) and translation (D). (B) Possible pathways of both nutrient and nonnutrient secretagogues that are thought to be involved in insulin secretion. (B1) Glucagon, GIP, etc. bind to cell surface receptors that are coupled to AC via the heterotrimeric GTP-binding protein G s . Receptor binding activates AC, which produces cAMP from ATP. cAMP binds to PKA, resulting in phosphorylation and activation of insulin secretion promoting proteins. Additionally, PKA, together with Ca 2+ , activates the CREB transcription factor which induces, amongst others, insulin gene transcription. (B2) The neurotransmitter acetylcholine and the gastrointestinal hormone cholecystokinin affect insulin secretion by binding to receptors associated with the heterotrimeric GTP-binding protein G q coupled to PLC. Activation of PLC leads to hydrolysis of PIP 2 with concordant production of IP 3 and DAG. IP 3 stimulates release of Ca 2+ from the endoplasmic reticulum, activates CaMK and thereby stimulates insulin secretion. The plasma membrane-bound DAG activates PKC, which translocates from the plasma membrane to the cytosol and phosphorylates a number of proteins that facilitate insulin secretion. (B3) The autocrine effect of insulin on insulin secretion. Although debate is ongoing as to whether insulin secretion is negatively or positively affected by insulin, it is thought to be mediated by PI3K. AC, adenylate cyclase; CaMK, Ca 2+ / Calmodulin-dependent protein kinase II; DAG, diacylglycerol; ETC, electron transport chain; G, glucose; GIP, glucose-dependent insulinotropic polypeptide; IP 3 , inositol triphosphate; P, pyruvate; PIP 2 , phosphatidylinositol bisphosphate; PK, protein kinase; PLC, phospholipase C; RRP, ready releasable pool; TCA, tricarboxylic acid cycle Besides glucose, other nutrient and non-nutrient secretagogues actively regulate beta cell function, presumably by binding to their respective membrane-bound receptors followed by activation of intracellular signal transduction pathways (Fig. 1 , see labels B1, B2 and B3) [12] .
At the whole body level, insulin secretory capacity depends not only on the adequate functioning of the individual beta cells, but also on the total number of beta cells, which is physiologically regulated [15] . A multitude of potential hormonal regulators of beta cell growth and proliferation have been described, e.g. gastrin, epidermal growth factor, incretins, growth hormone and insulin(-like) molecules [15] . The G-protein/cAMP/cAMP response element-binding protein (CREB) and insulin/Akt systems are key signalling axes for beta cell survival and proliferation. In turn, glucose also potentiates signalling and regulates gene expression through the latter systems, thereby preserving the ability of beta cells to respond to growth stimulation (reviewed in [14] ).
Clearly, normal insulin production depends on a multitude of signal transduction pathways in which many key regulators are present. Adequate glucose sensing not only rapidly regulates insulin synthesis and secretion, but, chronically, is also critical for the maintenance of the glucose-responsive state and the number of beta cells. The large number of regulating factors that can be manipulated relatively easily makes beta cell function a sensitive target for environmental pollutants.
Environmental pollutants and diabetes

Epidemiological evidence
The most convincing evidence for a relationship between diabetes and environmental pollutants comes from accidental or occupational exposures to high levels of these compounds [6] . One of the most striking examples is dioxin exposure, which has been positively linked to the elevated prevalence of type 2 diabetes in several populations, e.g. US Air Force veterans from the Vietnam war [6, 16] , dioxin-exposed individuals following the Seveso accident [17] , and populations living nearby [18] or working at [19] industrial plants producing dioxin-containing pesticides or herbicides. Apart from dioxin, other environmental pollutants have been epidemiologically associated with type 2 diabetes, as summarised in Table 1 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (reviewed in [6] ).
Associations, however, do not necessarily imply a causal link. It is possible that diabetic individuals have a reduced capacity to excrete or metabolise pollutants, or that compounds might actively contribute to disease development and progression. In-depth investigation of the effect of chemicals on the processes leading to the development of diabetes is thus required. As deterioration of beta cell function has a key role in diabetes development, it is unsurprising that the first indication of the possible involvement of environmental pollutants in diabetes onset or progression came from experimental studies investigating mechanisms and effects on insulin secretion.
Experimental evidence: effects on beta cell function
Oestrogens and xenoestrogens
Although long considered a plain sex hormone, it is now acknowledged that 17β-oestradiol (E 2 ) plays an important role in the function of the cardiovascular, musculoskeletal, immune and central nervous systems [40] . Moreover, E 2 has recently been linked to alterations in whole body glucose homeostasis [41] . The most powerful evidence comes from situations where oestrogen levels are outside the physiological range, such as in menopause or pregnancy. Both are considered to be risk factors for diabetes development [42] .
With regard to the underlying mechanisms, AlonsoMagdalena et al. [43] showed that oestrogens have direct acute and chronic effects on beta cell function and that different receptors mediate oestrogen action. They demonstrated that chronic E 2 treatment increases the insulin content of beta cells, thereby enabling the cells to secrete more insulin without altering pancreatic beta cell mass or viability. Experiments using oestrogen receptor (ER) knockout mice (both ERα and ERβ, Esr1 −/− and Esr2 −/− ) established that direct activation of ERα in vivo and in vitro regulates pancreatic insulin levels [43, 44] . Furthermore, oestrogen-mediated protection of beta cells from injury-stimulated apoptosis also depends on binding to ERα [45] .
Administration of physiological E 2 concentrations in vivo and in vitro acutely stimulates GSIS [46, 47] . This rapid response is characterised by increased cGMP levels, activating protein kinase G, which closes K ATP + channels. This, in turn, causes membrane depolarisation, and the resulting increase in the intracellular free calcium concentration ([Ca 2+ ] i ) enhances glucose-induced signals [46] and insulin secretion. Additionally, the E 2 -stimulated increase in [Ca 2+ ] i rapidly activates the CREB transcription factor, which plays a key function in beta cell survival and division [48] . In this manner, E 2 initiates a signalling pathway at the plasma membrane that rapidly modifies nuclear function [49] . Initially, Nadal et al. [46] suggested that the rapid responses of beta cells to E 2 are mediated by a non-classical membrane ER (ncmER), but recently they indicated that acute oestrogen effects are probably the result of binding to an extra-nuclear ERβ [50] . Although two membrane molecules behaving as ncmERs were identified in beta cells, namely the sulfonylurea receptor and the G-proteincoupled oestrogen receptor (also known as GPER or GPR30) [51] , they only seem to trigger actions at pharmacological rather than physiological E 2 concentrations [44, 52, 53] . Thus, the specific contribution of each of these receptors (ERα, ERβ, ncmER) in oestrogen-mediated effects on insulin storage and secretion is still not fully known.
Based on these findings, Alonso-Magdalena et al. [43] suggested that environmental oestrogens or xenoestrogens might have a role in the aetiology of type 2 diabetes. They hypothesised that if the positive effect of E 2 on beta cell function and insulin secretion is taken a step further, prolonged exposure to high oestrogen levels could hyperactivate beta cells. At the whole body level, the ensuing sustained hyperinsulinaemia would be able to induce peripheral insulin resistance and glucose intolerance. This chain of events, commonly referred to as the metabolic syndrome, can explain discrepancies in epidemiological data regarding the beneficial or detrimental effects of oestrogens on glucose homeostasis: a direct stimulatory and protective effect on the beta cell, which, when inappropriately activated, results in insulin secretion not justified by the prevailing glucose concentration. Therefore, the presence of compounds that mimic the actions of E 2 , socalled xenoestrogens, could profoundly affect normal insulin metabolism and beta cell function. Experiments with bisphenol A provide supporting evidence that environmental oestrogens are strong candidates for the exacerbation and acceleration of the development of type 2 diabetes [47] .
Bisphenol A has been shown in multiple independent studies, both in vitro (reviewed in [54] ) and in vivo (reviewed in [55] ), to act as a xenoestrogen and is registered as an EDC [42] in, among other places, the European Union [56] . Although EDCs were initially linked to effects on the reproductive system and thyroid, nowadays it is recognised that other hormonal and physiological systems may also be fundamentally affected. Supporting evidence comes from the association between EDCs and the metabolic syndrome [42] .
Until recently, bisphenol A was considered to be a weak oestrogen because in some bioassays (e.g. uterotrophic assays, in vitro receptor binding assays), it can be up to 100,000-fold less potent than E 2 [57] . However, bisphenol A is as potent as E 2 in its effects on beta cell function [47] . In terms of rapid effects on insulin secretion, it has been shown that the dose bisphenol A needed to increase insulin secretion is the same as the dose of E 2 . As for E 2 , both changes in [Ca 2+ ] i [51] and CREB phosphorylation and activation [48] are reported. An in vivo experiment showed that bisphenol A rapidly increases plasma insulin and decreases blood glucose values [47] . Because this rapid response is unaffected by the administration of an antioestrogen that blocks the classical ERs, the authors suggested that it is mediated by ncmER [47] , although they later declared that these receptors are more likely to trigger their actions at pharmacological E 2 concentrations and that ERβ might be the responsible receptor [50] .
Long-term treatment with bisphenol A causes the pancreatic insulin content to increase, and this increase is completely abolished when anti-oestrogens are administered [47] . [42] . Since the mouse insulin gene does not contain an oestrogen response element (ERE), the equally effective upregulation of the insulin content by bisphenol A relative to E 2 cannot be explained by the classic pathway of ER-ERE binding [42] . One possible explanation is that bisphenol A could act via ERα through other mechanisms, such as activation of other transcription factors or activation of protein kinases through extra-nuclear ERα.
The findings on the equal potency of bisphenol A and E 2 with respect to effects on pancreatic beta cells are in line with recent developments on the controversial oestrogenicity of bisphenol A [47] . Current opinion holds that bisphenol A is a selective oestrogen receptor modulator and thus its potency and mode of action can vary between different tissues and even between different cell types in the same tissue (reviewed in [57] ).
Strengthened by the demonstration of an association between bisphenol A concentrations and diabetes prevalence (Table 1) [31], the above-mentioned studies show that some xenoestrogens are able to alter beta cell function at environmentally relevant doses and thus might be an additional risk factor for diabetes development or progression. However, the modus operandi of other xenoestrogens (e.g. diethylstilbestrol, nonylphenol) remains to be elucidated.
Although our knowledge of how oestrogenic compounds such as bisphenol A, nonylphenol and diethylstilbestrol interfere with insulin homeostasis is far from complete, the disruptive effect of other classes of compounds is much less known. Figure 2 gives an overview of the chemicals for which a mechanism has been proposed and how they might affect insulin secretion.
Organophosphorus compounds
Organophosphorus compounds (OPCs) are cholinesteraseinhibiting chemicals that are mainly used as pesticides. Inhibition of acetylcholinesterase and the subsequent accumulation of the neurotransmitter acetylcholine at nerve synapses is also the suggested mechanism for OPC toxicity in non-target species [58, 59] . Many OPCs and their metabolites have been shown to be carcinogenic EDCs. They interfere with oestrogen action and thyroid hormones by specifically increasing the expression of oestrogenresponsive genes [60] and preventing thyroid hormonereceptor binding, respectively [61] . The induction of pancreatitis after OPC exposure indicates that OPCs might be able to specifically target pancreatic tissue [62, 63] . That hyperglycaemia is frequently reported and is considered to be one of the main adverse effects of OPC poisoning in humans and animals is suggestive of specific targeting of the endocrine pancreas by these compounds. The unbalanced glucose homeostasis is probably due to inhibition of acetylcholinesterase at central and peripheral synapses that act in the endocrine regulation of glucose metabolism [64] . Although OPC exposure could possibly be linked to insulin resistance [65] , little is known about the impact of OPCs on pancreatic beta cells and the molecular mechanisms supporting this disruption. Malathion is currently one of the most studied OPCs with respect to the mechanisms underlying hyperglycaemia. Remarkably, in vitro and in vivo studies on the effect of malathion on pancreatic beta cells provide contradictory results. In vitro data report a higher insulin content but lower insulin secretion by islets isolated from malathion-treated rats [65, 66] , whilst reports of subchronic exposures to malathion in vivo show a significant increase in plasma insulin and glucose levels [59, [65] [66] [67] .
In an attempt to disentangle the molecular mechanisms that underlie the malathion-induced increase in insulin secretion in vivo, Pournourmohammadi et al. [65] proposed a role for acetylcholine itself. Through interaction with muscarinic M 3 receptors, accumulating acetylcholine is thought to increase GSIS, either through a rise in [Ca 2+ ] i or through affecting the efficacy of Ca 2+ in stimulating exocytosis [68] , as frequently observed in other tissues [65] . Additionally, the activation of key enzymes involved in insulin secretion, namely glutamate dehydrogenase and glucokinase, has been suggested to explain the malathion-induced increase in insulin secretion (Fig. 2) [67] .
Vosough-Ghanbari et al. [66] made further progress in defining the role of Ca 2+ in pancreatic malathion toxicity. The authors proposed that a malathion-stimulated increase in Ca 2+ levels could cause a functional loss of Ca 2+ / calmodulin-dependent protein kinase, a protein associated with insulin secretory granules that is probably involved in exocytosis or insulin granule transport, thereby decreasing Ca 2+ -induced insulin secretion. However, malathion exerts its cytotoxic effects by induction of apoptosis via a direct effect on the islet's mitochondrial function [65] , [Ca 2+ ] i elevation, generation of reactive oxygen species (ROS), and depletion of ATP [66] (Fig. 2) . Therefore, the observed [Ca 2+ ] i increase is not a direct indication of insulin secretion, since it is also increased during apoptosis, another known action of malathion in pancreatic cells.
Apart from malathion, diazinon and dimethoate are commonly used OPCs that have been shown to elevate plasma glucose levels while decreasing plasma insulin levels [58, 64] . Both compounds induced oxidative/nitrosative stress in islets of Langerhans, and diazinon produced insulin insufficiency [58] . Diazinon-mediated changes in the cholinergic system could also influence insulin secretion (in a similar manner to malathion; Fig. 2 ). Other OPCs, including dichlorvos [69] (Table 1 ) and formothion [70] , have previously been reported to have hyperglycaemic effects, but molecular and mechanistic evidence is still missing.
The literature cited above clearly indicates that OPCs have the capacity to disrupt beta cell function and warns of their diabetes-inducing potential, since both hyperinsulinaemia and hyperglycaemia were reported. However, caution should be exercised when seeking to implicate OPCs as one of the main mechanisms of diabetes development because OPC poisoning has also been related to pancreatitis, which is a risk factor for diabetes development.
POPs
POPs are organic chemicals that are persistent and widely distributed in the environment, have bioaccumulative properties and are toxic to humans and wildlife [71] . Studies have linked POPs to a large spectrum of adverse effects on wildlife species and humans, such as reproductive, developmental, behavioural, neurological, endocrine and immunological alterations. Several POPs have been suggested to be potential EDCs, as they affect fertility, reproduction [72] and thyroid hormone signalling [73] in both wildlife and humans. POPs have also recently been linked to the development of pathologies associated with the metabolic syndrome, including type 2 diabetes, liver and cardiovascular disease ( Table 1 ). In spite of numerous links with disruption of glucose homeostasis (e.g. hyperglycaemia, hyperinsulinaemia, diabetes), these studies are suggestive, though inconclusive, with regard to environmental contaminants as aetiological agents for diabetes and other metabolic diseases.
One of the most investigated POPs related to adverse effects on glucose and lipid metabolism is the extremely toxic 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Several hormone systems in different cell types and tissues and at different developmental stages are being altered by dioxin [74] , leading to a complex disruption of multiple endocrine systems. One of the most common symptoms seen in animal species after TCDD exposure is loss of body weight or reduced weight gain [75] , commonly referred to as wasting syndrome [76] . Since hypophagia, hyperlipidaemia and hypertriglyceridaemia are observed in TCDD-induced alterations in body weight, the assumption is made that affected animals are unable to utilise the energy-rich nutritional compounds available in their blood. Metabolic derangements related to glucose metabolism have been considered to play a crucial role in the induction of this wasting syndrome [75] . The most important reported effects of TCDD on glucose homeostasis are the reduction of glucose uptake by adipose tissue, liver and pancreas (in vivo as well as in vitro) [77, 78] , accompanied by decreased insulin production and secretion by the pancreatic beta cells [79] . The biological basis of this decline is still unclear, but TCDD probably affects GSIS by different mechanisms (Fig. 2) . First, glucose transport is thought to be reduced as a consequence of TCDD binding to the aryl hydrocarbon receptor [75] . This causes changes in translational and transcriptional mechanisms resulting in diminished GLUT expression, amongst other effects [77, 78, 80] . Furthermore, abolishment of glucose-induced Ca 2+ influx and mitochondrial alterations are assumed to be important factors in dioxin-reduced GSIS [81] .
Another suggestion concerning beta cell dysfunction is that TCDD exposure could affect the activity of pancreatic nitric oxide synthase (NOS) [82] . Although the exact function of NOS in pancreatic beta cells is still unknown, multiple studies [83] point to an important negative control of the enzyme on pancreatic beta cell function [84] , although paradoxically low nitric oxide levels are noted to have positive effects [83] . As such, environmental toxicants capable of affecting NOS activity need to be tested for their potential to disrupt insulin secretion and metabolism.
Compared with TCDD, the effects of polychlorinated biphenyls (PCBs) on insulin secretion are less thoroughly studied and mechanistic information is sparser. To investigate PCB toxicity, Fischer et al. [85] exposed rat insulinoma RINm5F cells to a commercial mixture of PCBs (Aroclor 1254; Monsanto, St Louis, MO, USA) and three specific PCB congeners (two non-coplanar congeners [PCB-153, PCB-47] and one coplanar congener ). The observed concentration-dependent increase in insulin secreted in cell culture medium for both Aroclor 1254 and the non-coplanar congeners suggest a secretagogue-like effect. This stimulation probably results from a mechanism that includes an increase in [Ca 2+ ] i followed by activation of a Ca 2+ /calmodulin-dependent protein kinase [86] (Fig. 2) .
In summary, the studies described above provide the first evidence of a possible mechanistic link between glucose metabolism disorders and low-level POP exposure. This information on the effects of PCBs and TCDD on insulin secretion clearly indicates that a more detailed and comprehensive investigation of the targeted effects of these environmental pollutants on beta cells and their involvement in type 2 diabetes development and progression is needed.
Metals
Several metals, such as cadmium, mercury and the metalloid arsenic, have been epidemiologically linked to the incidence of type 2 diabetes (reviewed in [87, 88] ). The ability of metals to disrupt insulin secretion was first reported in the 1970s [89] . In this study, cadmium was suggested to have an inhibitory effect on the secretory activity of pancreatic beta cells, mediated by interference with calcium uptake. A decade later, it was suggested that at low concentrations cadmium stimulates insulin secretion, while high levels result in a significantly diminished rate of insulin release [90] . Moreover, in the Third National Health and Nutrition Examination Survey, cadmium was related with both impaired fasting glucose and diabetes [37] . In rats, chronic and subchronic cadmium exposure resulted in an accumulation of cadmium in the pancreas and reduced serum insulin levels, suggesting a possible direct toxic effect of cadmium on the pancreas [88, 91] . In an attempt to unveil the underlying mechanism, Lei et al. [91] proposed that cadmium affects insulin transcription and translation (Fig. 2) . However, a clear outline of its mode of action has not yet been published.
Arsenic seems to affect pancreatic beta cells by the induction of oxidative stress [92] and the reduction of insulin transcription and secretion [93] . The latter was deduced from altered expression of the following genes: (1) Pdx1 (previously known as Iuf1) [93] [94] [95] , a transcription factor that is essential for pancreas development, insulin production and glucose homeostasis [96] ; and (2) the insulin gene [97] . Other studies reported effects on glucose uptake, induction of ROS production, interference with the activity of key antioxidant enzymes [98] , apoptosis, necrosis and inflammation reactions [39, 93] (Fig. 2) .
Mercury, as mercuric chloride (HgCl 2 ), has also been shown to target the pancreas by altering intracellular Ca 2+ homeostasis in beta cells and decreasing insulin secretion from toadfish islets [99] . The association between type 2 diabetes and the Minamata disease (methylmercury [MeHg] poisoning) in Japan has further underlined the idea of the existence of mercury-induced beta cell damage [100] . The mechanism of action of mercury on pancreatic beta cells is still largely unknown. However, Chen et al. [100] examined the role of the phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway in mercury-exposed mice (in vitro and in vivo) and showed that insulin secretion is inhibited whereas oxidative stress and PI3K activation are induced. Both, PI3K and ROS are implicated in Akt signalling pathway-dependent pancreatic beta cell dysfunction.
Humans at risk?
Although the studies described above clearly indicate that some environmental pollutants are able to alter beta cell function, it has yet to be determined whether the prevailing environmental concentrations of pollutants can be a risk factor for diabetes. A first hint that the general population is exposed to concentrations that may increase diabetes prevalence is derived from epidemiological studies (Table 1) . However, clear causality between human exposure to pollutants and diabetes is so far lacking. An important problem is the fact that the majority of mechanistic studies employ exposure concentrations far above the concentrations found in the human population. To allow profound risk assessment, however, more experimental data at environmentally relevant concentrations are needed. Current risk assessments predominantly use no or lowest observed adverse effect levels (NOAEL/ LOAEL), preferably derived from chronic animal studies or, if available, human exposure data to calculate acceptable daily intake doses or reference doses (RfD). Both are expressed in grams per kilogram per day. To extrapolate data from animal studies, uncertainty factors are used to account for, for example, species differences, length of exposure, LOAEL or NOAEL.
An overview of compound concentrations used in the cited mechanistic studies and compound RfD, if available, is presented in Table 2 . At first sight the concentrations used in mechanistic (in vivo) studies are notably higher than the RfD determined by the US Environmental Protection Agency (EPA). However, low doses of bisphenol A (10-100 μg kg −1 day [103] . Since malathion in doses of 10 to 20 mg kg −1 day −1 fed to rats for 4 weeks altered blood glucose and insulin values, Panahi et al. [67] suggested that the previously determined NOAEL and the derived acceptable daily intake dose [103] for humans should be re-evaluated. At present, the US EPA oral RfD for malathion is set at 20 μg kg −1 day −1 [104] , and this was determined using a study of volunteers who had an oral intake of 8, 16 or 24 mg/day of malathion. In this study, the NOAEL was 16 mg/day (equivalent to 0.27 mg kg did not include this NOAEL value because they argued that, considering the age of the study, it was likely that the administered malathion contained toxic impurities. Although the RfD of malathion is debatable, this illustrates that the malathion concentrations producing diabetogenic effects in rat might be relevant to humans, and further research on its potential to interfere with processes involved with diabetes development and progression could give valuable information for risk assessment.
For all other compounds discussed in this review the studied concentrations are high compared with exposure levels of the general population and with concentrations that cause, for example, teratological, reproductive and developmental effects or cancer. For instance, the RfD for TCDD was very recently proposed to be set at 0.7 pg kg −1 day −1 based on LOAEL (±20 pg kg
values in human studies looking at endocrine related endpoints (sperm count and thyroid-stimulated hormone concentrations), but is still under review by the US EPA [105] . In acute in vivo studies investigating effects on beta cell function, concentrations of 1-50 μg/kg are used [79] , which are far higher than the RfD. The suggested diabetogenic potential might thus be a minor factor in the risk assessment of these compounds, because other deleterious effects are observed at much lower concentrations. However, some effects manifest themselves acutely, while others manifest themselves more chronically. The time period necessary for a compound to exert its diabetogenic properties in humans has not been investigated so far, but for the example of TCDD only acute (several hours to 10 days) in vivo effects on rabbits were monitored [79] .
Because of the lack of information, it is not currently possible to draw conclusions regarding the importance of the diabetogenic effect of these compounds relative to other observed harmful effects. Based on the findings for certain compounds, such as bisphenol A and malathion, inclusion of the diabetogenic properties might be interesting for estimations of safe acceptable daily intake or RfD values. Because the concentrations of compounds used in mechanistic studies are much higher than those commonly encountered in the environment, these mechanistic studies cannot provide direct information on compound toxicity in human-relevant exposure scenarios. In assessing the risk of a compound, direct extrapolation of concentration levels from simple experimental studies is not always accurate, since more complex exposure scenarios should be considered, such as long-term exposure to low concentrations, mixture effects and exposure during critical stages of development. Moreover, although the applied concentrations are higher than the exposure levels for the human population, specific effects of compounds on the pancreatic beta cell are indicative of a targeted interaction with certain regulatory pathways [102] . The pathways that are altered by, for instance, TCDD might also be triggered by other dioxin-like compounds (e.g. dioxin-like PCBs, polychlorinated dibenzofurans, polybrominated dibenzodioxins/furans). Additionally, since humans are exposed to a variety of compounds, mixtures may exert an effect even at NOAELs of individual compounds. Many compounds act by binding through receptors (oestrogenic compounds to ERs, dioxin-like compounds to the aryl hydrocarbon receptor, etc), which may lead to additive or synergistic effects of the individual compounds. Background information that was provided in (most of) the mechanistic studies to explain the choice of the exposure dose is summarised. To compare the doses used in the experimental studies, the US EPA reference dose, with the NOAEL or LOAEL values, model species (Org) and uncertainty factors (UF) on which their calculations were based was derived from the Integrated Risk Information system of the US EPA [106] . Compounds are discussed in order of appearance
For the IUPAC names of chemicals mentioned in this table, please see ESM Table 1 NR, not reported
Concluding remarks and future directions
The prevalence of diabetes mellitus is currently at epidemic proportions and is a cause of great concern, not only for human health, but also because of its social and economic implications. Although genetic predisposition, obesity, diet and lack of exercise are commonly accepted causes of the development of type 2 diabetes, it is argued that these factors alone cannot fully explain the rapid rise in the prevalence of diabetes. The environment and, more specifically, environmental pollutants are mentioned as major interfering candidates. Although a large variety of compounds have been shown to be epidemiologically correlated with the occurrence of type 2 diabetes, detailed mechanistic information on how these pollutants interfere with insulin metabolism is lacking. Therefore, the present review gives an overview of the available information linking environmental pollutants with type 2 diabetes, specifically focusing on the crucial player in diabetes development, the beta cell. Although the data are sparse and fragmented, pancreatic beta cells are clearly at risk to be targeted by pollutants. Therefore, more research efforts on the interaction of compounds with beta-cell function and/or mass in animal models at human relevant concentrations are needed to further evaluate the hypothesis that environmental pollutants can be additional risk factors for diabetes development. Disentangling the pollutant's modus operandi aids to the elucidation of the underlying pathways that regulate beta cell function and hereby might reveal key regulator and signalling genes and molecules targeted by and susceptible for xenobiotic chemicals. Mechanistic studies in combination with long term in vivo exposures at low doses and multigenerational studies in animal models, will definitely ameliorate risk assessment. Simultaneously, more targeted epidemiological research should be undertaken and broadened towards the general population. Only with in-depth information on different exposure scenarios and effect levels can conclusions be made concerning human risk.
